Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies for cancer, focusing on B-cell malignancies. Its core products include CRG-023, a tri-specific autologous CAR T therapy targeting CD19, CD20, and CD22 antigens, and a universal allogeneic vector platform designed to overcome immune rejection and manufacturing challenges. CARGO aims to enhance durability, safety, and patient access through innovative cell engineering and manufacturing technologies.
This description was generated via AI from an annual report. Updated about 1 year ago.